In 2012, the International Federation of Obstetrics and Gynecology (FIGO) produced a chart detailing recommended dosages of misoprostol when used alone, for a variety of gynecologic and obstetric indications. In light of new evidence and through expert deliberation, this chart has now been revised and expanded. Some areas were particularly challenging to develop given the limited, low-quality, or inconsistent evidence. This commentary is intended to explain some of the changes and decisions made.